Keep knowledgeable with free updates
Merely signal as much as the Prescription drugs sector myFT Digest — delivered on to your inbox.
European pharmaceutical bosses have known as on the EU to extend drug costs in direction of the a lot greater ranges paid by the US, saying it can encourage innovation.
In a letter to the Monetary Instances, Novartis chief govt Vas Narasimhan and Paul Hudson, his counterpart at Sanofi, say the European Fee ought to set a spending goal for medicines and vaccines to “fairly reward innovation”.
The US pays practically 3 times as a lot for branded and generic medicines as different comparable international locations, in accordance with US authorities estimates. The fee ought to create a benchmark for its member states “in the range of US net prices”, the chief executives say of their letter, including that this could possibly be adjusted although rebates for some international locations.
Decrease costs within the EU “artificially [cap] biopharma market growth” and creates a “clear disincentive for innovators”, Narasimhan and Hudson add, citing knowledge that 30 per cent of medicines accepted within the US are usually not out there in Europe after two years.
As the specter of tariffs hangs over the trade, the executives spotlight main pharma investments within the US since Donald Trump returned to energy and say Europe ought to act “urgently or decline will set in and [the] departure of companies will accelerate”.
The Trump administration has promised to handle excessive drug costs within the US. Throughout his first presidential time period, Trump pushed for costs to be pegged to comparable international locations.
Whereas an govt order issued final week didn’t do that, a US official mentioned the federal government was “very focused on narrowing the delta between what the United States gets for prices versus what other developed nations do”.
That might current a problem to the pharmaceutical trade, which depends on the US for between 40 and 50 per cent of its gross sales.
The European chief executives say of their letter: “Against a backdrop of waning European biopharma competitiveness, the uncertainty of tariffs is further reducing incentives to invest in the EU.”
They add that they face stiff competitors from China, the second largest pharmaceutical market after the US, which has “expanded its position by attracting multinationals and created a vibrant biotechnology environment”.
The trade has rushed to announce massive US investments to attempt to see off the specter of tariffs. Prescription drugs have been excluded from US tariffs introduced this month however the administration is pursuing an investigation that might outcome of their introduction.
Roche mentioned this week that it could make investments $50bn within the US, Novartis has pledged $23bn of spending on manufacturing and R&D and US drugmakers Johnson & Johnson and Eli Lilly have each promised main investments.
Sanofi has not but made any massive US funding announcement. French President Emmanuel Macron has urged European firms to pause US funding because the fee prepares a response to tariffs.
An EU official mentioned dialogue with the pharma trade was “ongoing”. Fee president Ursula von der Leyen met chief executives this month to debate the potential tariffs and the bloc’s response.
